<DOC>
	<DOCNO>NCT00357084</DOCNO>
	<brief_summary>RATIONALE : Methotrexate glucocorticoid therapy , prednisone methylprednisolone , may effective treatment acute graft-versus-host disease cause donor stem cell transplant . PURPOSE : This phase II trial study well give methotrexate together glucocorticoid work treat patient newly diagnose acute graft-versus-host disease donor stem cell transplant .</brief_summary>
	<brief_title>Methotrexate Glucocorticoids Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : - Determine , within limit phase II study , whether low-dose methotrexate accelerate withdrawal glucocorticoid decrease nonrelapsing mortality patient newly diagnose acute graft-versus-host disease ( GVHD ) undergo nonmyeloablative allogeneic hematopoietic stem cell transplantation ( HSCT ) . - Determine tolerability low-dose methotrexate glucocorticoid treat newly diagnose acute GVHD patient . OUTLINE : This cohort study . Patients receive concurrent low-dose methotrexate glucocorticoid treatment acute graft-versus-host disease ( GVHD ) . Patients receive first dose methotrexate IV ≥ 12 hour initiation glucocorticoid treatment ( glucocorticoid treatment initiate ) second dose 72 hour dose 1 . Patients receive subsequent dos methotrexate IV orally weekly 1 year* resolution GVHD absence recurrent malignancy , refractory chronic GVHD , administration secondary treatment GVHD , unacceptable toxicity . NOTE : *Treatment low-dose MTX may continue beyond 1 year discretion manage physician . Patients receive glucocorticoid therapy comprise prednisone methylprednisolone IV twice daily objective evidence improvement GVHD manifestation . Patients resolve significantly improve GVHD receive treatment 10 day follow accelerated taper total 72 day treatment case flare GVHD glucocorticoid taper . Patients exacerbation recurrence GVHD accelerate taper treat ≥ 1 week resume less rapid taper . Patients develop GVHD progression primary refractory GVHD may receive secondary systemic therapy discretion manage physician . After completion study treatment , patient follow 1 year annually thereafter . PROJECTED ACCRUAL : A total 53 patient accrue study .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute graftversushost disease ( GVHD ) Has undergone nonmyeloablative allogeneic hematopoietic stem cell transplantation ( HSCT ) HLAmatched related unrelated donor ≥ 14 day ago Treatment GVHD glucocorticoid indicate 1 follow criterion : Initial treatment prednisone methylprednisolone 2 mg/kg indicate ( judgement attend physician ) following : Severity GVHD require hospitalization GVHD manifestation include symptom anorexia , nausea , vomit GVHD begin within 23 week HSCT GVHD manifestation progress rapidly 1 day next treatment Initial treatment prednisone methylprednisolone 1 mg/kg produce adequate clinical improvement within first 4 day ( judgement attend physician ) No pleural effusion ascites ( i.e. , freeflowing fluid lateral decubitus view ) Mere blunt costophrenic angle posterior anterior chest xray sufficient No GVHD donor lymphocyte infusion No hallmarks chronic GVHD No bronchiolitis obliterans PATIENT CHARACTERISTICS : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study treatment No severe mucositis ( grade 3 4 ) indicate erythema , edema , ulceration require hydration , parenteral nutritional support , intubation result aspiration pneumonia Absolute neutrophil count ≥ 1,500/mm^3 Bilirubin ≤ 2 time upper limit normal ( ULN ) ( unless abnormality attributable GVHD ) AST ALT ≤ 2 time ULN ( unless abnormality attributable GVHD ) Creatinine clearance ≥ 50 mL/min PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior prednisone methylprednisolone 2 mg/kg &gt; 72 hour 1 mg/kg &gt; 96 hour Concurrent topical therapy , include psoralen ultraviolet A irradiation ( PUVA ) , glucocorticoid cream , oral beclomethasone dipropionate , topical azathioprine , ophthalmic glucocorticoid allow No concurrent treatment GVHD</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>poor prognosis metastatic gestational trophoblastic tumor</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>